title: Clinical response to bevacizumab in schwannomatosis.
authors.affiliation: From The Johns Hopkins Hospital (J.O.B., K.C.S., A.L.B., A.J.B.), Baltimore, MD; St. Mary's Hospital (D.G.E.), Manchester, UK; University of Alabama at Birmingham (B.K.); and NYU Langone Medical Center (D.Z., M.A.K.), New York.
authors.forename: Jaishri
authors.initials: J
authors.lastname: Blakeley
authors.affiliation: From The Johns Hopkins Hospital (J.O.B., K.C.S., A.L.B., A.J.B.), Baltimore, MD; St. Mary's Hospital (D.G.E.), Manchester, UK; University of Alabama at Birmingham (B.K.); and NYU Langone Medical Center (D.Z., M.A.K.), New York. ksolt1@jhmi.edu.
authors.forename: Karisa C
authors.initials: KC
authors.lastname: Schreck
authors.affiliation: From The Johns Hopkins Hospital (J.O.B., K.C.S., A.L.B., A.J.B.), Baltimore, MD; St. Mary's Hospital (D.G.E.), Manchester, UK; University of Alabama at Birmingham (B.K.); and NYU Langone Medical Center (D.Z., M.A.K.), New York.
authors.forename: D Gareth
authors.initials: DG
authors.lastname: Evans
authors.affiliation: From The Johns Hopkins Hospital (J.O.B., K.C.S., A.L.B., A.J.B.), Baltimore, MD; St. Mary's Hospital (D.G.E.), Manchester, UK; University of Alabama at Birmingham (B.K.); and NYU Langone Medical Center (D.Z., M.A.K.), New York.
authors.forename: Bruce R
authors.initials: BR
authors.lastname: Korf
authors.affiliation: From The Johns Hopkins Hospital (J.O.B., K.C.S., A.L.B., A.J.B.), Baltimore, MD; St. Mary's Hospital (D.G.E.), Manchester, UK; University of Alabama at Birmingham (B.K.); and NYU Langone Medical Center (D.Z., M.A.K.), New York.
authors.forename: David
authors.initials: D
authors.lastname: Zagzag
authors.affiliation: From The Johns Hopkins Hospital (J.O.B., K.C.S., A.L.B., A.J.B.), Baltimore, MD; St. Mary's Hospital (D.G.E.), Manchester, UK; University of Alabama at Birmingham (B.K.); and NYU Langone Medical Center (D.Z., M.A.K.), New York.
authors.forename: Matthias A
authors.initials: MA
authors.lastname: Karajannis
authors.affiliation: From The Johns Hopkins Hospital (J.O.B., K.C.S., A.L.B., A.J.B.), Baltimore, MD; St. Mary's Hospital (D.G.E.), Manchester, UK; University of Alabama at Birmingham (B.K.); and NYU Langone Medical Center (D.Z., M.A.K.), New York.
authors.forename: Amanda L
authors.initials: AL
authors.lastname: Bergner
authors.affiliation: From The Johns Hopkins Hospital (J.O.B., K.C.S., A.L.B., A.J.B.), Baltimore, MD; St. Mary's Hospital (D.G.E.), Manchester, UK; University of Alabama at Birmingham (B.K.); and NYU Langone Medical Center (D.Z., M.A.K.), New York.
authors.forename: Allan J
authors.initials: AJ
authors.lastname: Belzberg
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000068258:Bevacizumab; D006801:Humans; D008297:Male; D009442:Neurilemmoma / Q000175:diagnosis* / Q000188:drug therapy*; D017253:Neurofibromatoses / Q000175:diagnosis* / Q000188:drug therapy*; D012878:Skin Neoplasms / Q000175:diagnosis* / Q000188:drug therapy*; D055815:Young Adult
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab